Caplin Point Laboratories
Caplin Point's unit gets USFDA nod for generic milrinone lactate injection
Pharma firm Caplin Point Laboratories Ltd on Wednesday said its arm Caplin Steriles Ltd has received final approval from the US health regulator for its generic milrinone lactate in 5 per cent dextrose injection indicated for the short-term intravenous treatment of patients with acute decompensated heart failure. The approval granted by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) milrinone lactate in 5 per cent Dextrose Injection of strengths 20 mg/100 mL and 40 mg/200 mL in single-dose infusion bags, Caplin Point Laboratories said in a regulatory filing. The approved injection is a generic therapeutic equivalent version of the reference listed drug PRIMACOR in dextrose 5 per cent, by Sanofi Aventis US LLC, it added. Milrinone is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure, the company said. Citing IQVIA (IMS Health) data, the company said milrinone lactate in 5 per cent ...
 "Caplin Point's unit gets USFDA nod for generic milrinone lactate injection")
Caplin Point share price hits record high after ANVISA clears Chennai plant
The facility was inspected between August 12 and 16, 2024, the company said.
 "Caplin Point share price hits record high after ANVISA clears Chennai plant")
Stocks to watch on Aug 19: Piramal Ent, Jubilant Pharmova, Urja Global
Stocks to watch on August 19: The promoters of the company have announced that on August 16, 2024, an entity within the Promoter Group acquired 616,615 equity shares of Piramal Enterprises
 "Stocks to watch on Aug 19: Piramal Ent, Jubilant Pharmova, Urja Global")
Caplin Point stock zooms over 5% on robust Q1 results; bottomline grows 20%
The surge in the stock price came after the company announced its June quarter of financial year 2025 (Q1FY25) results.
 "Caplin Point stock zooms over 5% on robust Q1 results; bottomline grows 20%")
Caplin Point rallies 12%, hits 52-week high on strong Q1 results
With a healthy order book, company targets 40-50 per cent growth in revenues in FY24.
 "Caplin Point rallies 12%, hits 52-week high on strong Q1 results")
Caplin Point rises 10% after arm gets USFDA nod for anti-inflammatory drug
So far this calendar year (CY23), shares of Caplin Point have declined 0.4 per cent, as against 1 per cent rise in the S&P BSE Sensex
 "Caplin Point rises 10% after arm gets USFDA nod for anti-inflammatory drug")
Caplin Point jumps 19%, hits record high; stock soars 37% in seven days
A combined 5.8 million equity shares, representing 7.6 per cent of the total equity of Caplin Point Laboratories, had changed hands on NSE and BSE till 12:56 pm
 "Caplin Point jumps 19%, hits record high; stock soars 37% in seven days")
Stocks to watch: TechM, ACC, Nestle India, 5paisa, Caplin Point, ICICI Pru
Ace investor Ashish Kacholia increased stake in Caplin Point from 1.08 per cent as of December 2020 to 1.16 per cent as of March 2021
 "Stocks to watch: TechM, ACC, Nestle India, 5paisa, Caplin Point, ICICI Pru")
Caplin Point up 20% on USFDA approval for Verapamil Hydrochloride injection
Verapamil Hydrochloride is a calcium channel blocker used in the treatment of cardiac conditions such as high blood pressure, arrhythmias and angina.
 "Caplin Point up 20% on USFDA approval for Verapamil Hydrochloride injection")
Bajaj Finance, Symphony: 10 stocks that have zoomed over 5,000% in 10 years
As many as 63 stocks have zoomed over 1,000 per cent during this period
 "Bajaj Finance, Symphony: 10 stocks that have zoomed over 5,000% in 10 years")
Caplin Labs gets USFDA nod for injection to prevent excessive blood loss
Caplin Steriles said it has developed and filed 11 ANDAs on its own and with partners, with 5 approvals so far
 "Caplin Labs gets USFDA nod for injection to prevent excessive blood loss")
Caplin's sterile injectable site in Chennai gets two USFDA observations
Caplin Point Laboratories said it believes these observations are procedural in nature and corrective
 "Caplin's sterile injectable site in Chennai gets two USFDA observations")
Caplin Point Lab hits 11-week high; stock surges 14%
The stock rallied 14% to Rs 430, trading at its highest level since November 16, 2018 on the BSE.
 "Caplin Point Lab hits 11-week high; stock surges 14%")
Caplin Point falls 11% on disappointing Q4 results
The stock fell 11% to Rs 532 on the BSE in intra-day trade after the company's ebitda margin in March quarter declined by 400bps to 35% from 39% in previous year quarter.
 "Caplin Point falls 11% on disappointing Q4 results")
Caplin Point Labs zooms over 40% in six days on strong Q4 results
The stock hit a new high of Rs 5784, rallied 41% in past six trading sessions from Rs 406 on May 10
 "Caplin Point Labs zooms over 40% in six days on strong Q4 results")
Caplin Point Lab surges 15% on strong Q4 results
The stock hit a 52-week high of Rs 467 after the company posted 114% growth in profit at Rs 33 cr
 "Caplin Point Lab surges 15% on strong Q4 results")
Caplin Point Lab zooms over 40% in three days post stock split
The stock hit a record high of Rs 414, rallied 42% in past three trading sessions from Rs 291 on October 18, 2016.
 "Caplin Point Lab zooms over 40% in three days post stock split")
